lexatumumab lexatumumab lexatumumab (also known as etr2-st01) is an experimental agonistic human monoclonal antibody against trail-r2 (dr5, apo-2), intended for the treatment of cancer. lexatumumabmonoclonal antibodytypewhole antibodysourcehumantargettrail-r2clinical dataatc codenoneidentifierscas number845816-02-6 nchemspidernoneunii967q0sjd77keggd06611 ychemical and physical dataformulac6346h9832n1720o2002s42molar mass143601.02 g·mol−1 ny (what is this?) (verify) hgs-etr2 antibodies were generated by human genome sciences through a collaboration with cambridge antibody technology. development was discontinued in 2015.